Biogen reported second-quarter earnings and revenue that topped estimates and hiked its full-year guidance as cost-cutting efforts showed progress and sales of its breakthrough Alzheimer's drug, ...

Biogen BIIB reported second-quarter 2025 adjusted earnings per share (EPS) of $5.47, which significantly beat the Zacks Consensus Estimate of $3.93. Earnings rose 4% year over year on a reported basis ...

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Biogen (BIIB) has moved quietly higher, with the share price ...

Biogen now expects full-year adjusted earnings to come in at $15.75 to $16.25 per share, up from a previous forecast of $15 to $16 per share. The biotech company also expects 2024 sales to decline by ...